Publications by authors named "Boris Shor"

Claim this Profile
T
The BCG Vaccine for COVID-19: First Verdict and Future Directions.
Maria Gonzalez-Perez, Rodrigo Sanchez-Tarjuelo, Boris Shor, Estanislao Nistal-Villan, Jordi Ochando

Front Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and anti-mitotic activity of 6,7-dihydro-4H-isothiazolo[4,5-b]pyridin-5-ones: In vivo and cell-based studies.
Victor V Semenov, Boris V Lichitsky, Andrey N Komogortsev, Arkady A Dudinov, Mikhail M Krayushkin, Boris Shor

Eur J Med Chem· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Alison M Betts, Nahor Haddish-Berhane, John Tolsma, Paul Jasper, Lindsay E King, Boris Shor

AAPS J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
Boris Shor, Jennifer Kahler, Maureen Dougher, Jane Xu, Michelle Mack

Clin Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Boris Shor, Hans-Peter Gerber, Puja Sapra

Mol Immunol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues.
Haiyin He, Anokha S Ratnayake, Jeffrey E Janso, Min He, Hui Y Yang, Boris Shor

J Nat Prod· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibody-based therapies in cancer: advances and challenges.
Puja Sapra, Boris Shor

Pharmacol Ther· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.
Boris Shor, Jiang Wu, Quazi Shakey, Lourdes Toral-Barza, Celine Shi

J Biol Chem· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Ker Yu, Celine Shi, Lourdes Toral-Barza, Judy Lucas, Boris Shor

Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting mTOR globally in cancer: thinking beyond rapamycin.
Boris Shor, James J Gibbons, Robert T Abraham, Ker Yu

Cell Cycle· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Ker Yu, Lourdes Toral-Barza, Celine Shi, Wei-Guo Zhang, Judy Lucas, Boris Shor

Cancer Res· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice.
Boris Shor, Druie Cavender, Crafford Harris

BMC Immunol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Boris Shor, Wei-Guo Zhang, Lourdes Toral-Barza, Jessica Lucas, Robert T Abraham

Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of a constitutively T-loop phosphorylated and active recombinant S6K1: expression, purification, and enzymatic studies in a high capacity non-radioactive TR-FRET Lance assay.
Wei-Guo Zhang, Boris Shor, Ker Yu

Protein Expr Purif· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cpc2/RACK1 is a ribosome-associated protein that promotes efficient translation in Schizosaccharomyces pombe.
Boris Shor, Jimmy Calaycay, Julie Rushbrook, Maureen McLeod

J Biol Chem· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis